Table 3 Summary of patients affected by respiratory-related adverse events
AEs classified as Respiratory, Thoracic and/or Mediastinal Disorders | |||||
|---|---|---|---|---|---|
Placebo | AZD9164 | ||||
GMAD, healthy subjects | n = 9 | 400 μg | 1000 μg | 2800 μg | Total (%) |
n = 6 | n = 6 | n = 6 | n = 27 | ||
Throat irritation | 1 (11.1) | 0 (0) | 1 (16.7) | 2 (33.3) | 4 (14.8) |
Oropharyngeal pain | 0 (0) | 1 (16.7) | 2 (33.3) | 0 (0) | 3 (11.1) |
Cough | 0 (0) | 0 (0) | 0 (0) | 1 (16.7) | 1 (3.7) |
Dyspnoea | 0 (0) | 0 (0) | 1 (16.7) | 0 (0) | 1 (3.7) |
JMAD, healthy subjects | n = 6 | 400 μg | 1000 μg | Total (%) | |
n = 6 | n = 6 | n = 18 | |||
Cough | 0 (0) | 1 (16.7) | 1 (16.7) | 2 (11.1) | |
Epistaxis | 0 (0) | 0 (0) | 1 (16.7) | 1 (5.6) | |
Nasal mucosal disorder | 0 (0) | 0 (0) | 1 (16.7) | 1 (5.6) | |
Respiratory tract infection | 0 (0) | 0 (0) | 1 (16.7) | 1 (5.6) | |
Upper respiratory tract infection | 0 (0) | 1 (16.7) | 0 (0) | 1 (5.6) | |
GMAD, COPD patients | n = 1 | n = 3 | n = 4 | ||
Dyspnoea | 1 (100) | 2 (66.7) | 2 (50) | ||
Cough | 0 (0) | 1 (33.3) | 1 (25) | ||